Business Context and Reporting Period
This Form 8-K reports on events occurring on July 24, 2020, specifically the results of Pavmed Inc.'s 2020 Annual Meeting of Stockholders. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York, New York. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols PAVM, PAVMZ, and PAVMW.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt levels, or liquidity ratios. The filing references prior debt instruments (Senior Secured Convertible Notes issued in November 2019 and April 2020) but does not disclose current balances or terms within this text.
Material Changes and Shareholder Actions
Stockholders representing approximately 81.5% of outstanding shares participated in the annual meeting. The following material actions were approved:
- Director Elections: Ronald M. Sparks and David S. Battleman, M.D. were re-elected as Class A directors.
- Debt Conversion Approvals: Shareholders approved the issuance of common stock to Alto Opportunity Master Fund entities (Alto B and Alto C) pursuant to Senior Secured Convertible Notes issued in November 2019 and April 2020, satisfying Nasdaq Listing Rule 5635.
- Charter Amendment: The authorized common stock was increased by 50,000,000 shares, from 100,000,000 to 150,000,000 shares. This amendment became effective on July 24, 2020.
- Equity Plan Amendments:
- The 2014 Long-Term Incentive Equity Plan share reserve was increased by 2,000,000 shares (total: 9,951,081).
- The Employee Stock Purchase Plan (ESPP) share reserve was increased by 500,000 shares (total: 750,000).
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
Guidance, Outlook, and Risks
This filing does not contain management guidance, financial outlook, or specific risk factor disclosures. The text notes that detailed descriptions of the convertible note transactions and plan amendments are incorporated by reference from the Definitive Proxy Statement filed on June 11, 2020.
Investor Verification Checklist
- Verify the impact of the 50,000,000 share increase in authorized capital on potential future dilution.
- Review the Definitive Proxy Statement (filed June 11, 2020) for full terms of the convertible notes with Alto Opportunity Master Fund.
- Confirm the specific conversion rates and share issuance details resulting from the approved debt conversions.
- Check subsequent filings for the actual issuance of shares under the amended 2014 Plan and ESPP.